BioWorld

Sep. 18, 2008

Biovail Gains Newly Approved HD Drug in $100M Prestwick Buyout

A month after winning FDA approval for its first drug, privately held Prestwick Pharmaceuticals Inc. was acquired by Canadian drugmaker Biovail Corp. in a $100 million deal. (BioWorld Today) Read More

Depomed Starts Hot Flash Phase III for Gabapentin GR

TLR-Independent, Intracellular Innate Immunity Activator Found

FDA Wants More Data for Gilead's CF Infection Drug

Other News To Note

Financings Roundup

Clinic Roundup

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...